Who is sponsoring NCT03962478?

NCT03962478 is sponsored by Xuzhou Central Hospital.

What condition does NCT03962478 study?

NCT03962478 studies Pancreatic Carcinoma, Biliary Obstruction.

Is NCT03962478 still recruiting?

NCT03962478 is currently completed. Last updated 30 September 2020.

Last reviewed 2020-09-30 · How we verify

NCT03962478: HIFU

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combined Stent Insertion and HIFU Ablation for Pancreatic Carcinoma With Biliary Obstruction

Completed NA Last updated 30 September 2020

What this trial tests

NA trial testing biliary stent and high-intensity focused ultrasound ablation system in Pancreatic Carcinoma in 92 participants. Completed in 28 September 2020.

Timeline

31 May 2019

Primary endpoint
8 February 2020

28 September 2020

Quick facts

Lead sponsor	Xuzhou Central Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	92
Start date	31 May 2019
Primary completion	8 February 2020
Estimated completion	28 September 2020
Sites	1 location across China

Drugs / interventions tested

biliary stent and high-intensity focused ultrasound ablation system
biliary stent

Conditions studied

Pancreatic Carcinoma — all drugs for Pancreatic Carcinoma →
Biliary Obstruction — all drugs for Biliary Obstruction →

Sponsor

Xuzhou Central Hospital

Who can join

Adults 18 to 80, any sex, with Pancreatic Carcinoma or Biliary Obstruction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare the clinical effectiveness and long-term outcomes between patients with pancreatic carcinoma and biliary obstruction who are treated by stent insertion with or without high-intensity focused ultrasound ablation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies.
Bazeed AY, Day CM, Garg S. · · 2022 · cited 42× · PMID 36077794 · DOI 10.3390/cancers14174257
Stent Insertion With High Intensity-Focused Ultrasound Ablation for Biliary Obstruction Caused by Pancreatic Carcinoma: A Randomized Controlled Trial.
Zhang FQ, Li L, Huang PC, Xia FF, et al · · 2021 · cited 4× · PMID 33605677 · DOI 10.1097/sle.0000000000000918

Verify or expand the search:

Other recruiting trials for Pancreatic Carcinoma

Currently open trials in the same condition.

NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07359586 — Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia · recruiting
NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting
NCT06995898 — The Vanguard Study: Testing a New Way to Screen for Cancer · NA · recruiting
NCT06807437 — Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula · Phase 3 · recruiting

Other Xuzhou Central Hospital trials

Trials by the same sponsor.

NCT06126289 — CSF Single-cell Sequencing and Proteomics of Chronic Postsurgical Pain in Patients With Lower Limb Fractures · unknown
NCT06136663 — Prevalence and Risk Factors for Postsurgical Pain After the Open Reduction and Internal Fixation of Lower Limbs. · unknown
NCT06050096 — DCB Treatment in CTO Guided by IVUS · unknown
NCT06395961 — Effect of New High Ankle Block on Wound Healing After the Operation of Debridement of Diabetes Foot · NA · enrolling by invitation
NCT05772026 — Plasma Proteomics in Patients With Postoperative Delirium · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03962478 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xuzhou Central Hospital
Last refreshed: 30 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03962478.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing